250 related articles for article (PubMed ID: 22205974)
1. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma.
Cambien B; Richard-Fiardo P; Karimdjee BF; Martini V; Ferrua B; Pitard B; Schmid-Antomarchi H; Schmid-Alliana A
PLoS One; 2011; 6(12):e28842. PubMed ID: 22205974
[TBL] [Abstract][Full Text] [Related]
2. Expression of CCL5 (RANTES) and CCR5 in prostate cancer.
Vaday GG; Peehl DM; Kadam PA; Lawrence DM
Prostate; 2006 Feb; 66(2):124-34. PubMed ID: 16161154
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5.
Nishikawa G; Kawada K; Nakagawa J; Toda K; Ogawa R; Inamoto S; Mizuno R; Itatani Y; Sakai Y
Cell Death Dis; 2019 Mar; 10(4):264. PubMed ID: 30890699
[TBL] [Abstract][Full Text] [Related]
4. Effect of CCR5 receptor antagonists on endocytosis of the human CCR5 receptor in CHO-K1 cells.
Longden J; Cooke EL; Hill SJ
Br J Pharmacol; 2008 Apr; 153(7):1513-27. PubMed ID: 18223665
[TBL] [Abstract][Full Text] [Related]
5. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.
Chang LY; Lin YC; Mahalingam J; Huang CT; Chen TW; Kang CW; Peng HM; Chu YY; Chiang JM; Dutta A; Day YJ; Chen TC; Yeh CT; Lin CY
Cancer Res; 2012 Mar; 72(5):1092-102. PubMed ID: 22282655
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.
Aldinucci D; Casagrande N
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772686
[TBL] [Abstract][Full Text] [Related]
7. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment.
Wang SW; Liu SC; Sun HL; Huang TY; Chan CH; Yang CY; Yeh HI; Huang YL; Chou WY; Lin YM; Tang CH
Carcinogenesis; 2015 Jan; 36(1):104-14. PubMed ID: 25330803
[TBL] [Abstract][Full Text] [Related]
8.
Battaglin F; Baca Y; Millstein J; Yang Y; Xiu J; Arai H; Wang J; Ou FS; Innocenti F; Mumenthaler SM; Jayachandran P; Kawanishi N; Lenz A; Soni S; Algaze S; Zhang W; Khoukaz T; Roussos Torres E; Seeber A; Abraham JP; Lou E; Philip PA; Weinberg BA; Shields AF; Goldberg RM; Marshall JL; Venook AP; Korn WM; Lenz HJ
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212126
[TBL] [Abstract][Full Text] [Related]
9. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
Baba M; Nishimura O; Kanzaki N; Okamoto M; Sawada H; Iizawa Y; Shiraishi M; Aramaki Y; Okonogi K; Ogawa Y; Meguro K; Fujino M
Proc Natl Acad Sci U S A; 1999 May; 96(10):5698-703. PubMed ID: 10318947
[TBL] [Abstract][Full Text] [Related]
10. Human MSCs promotes colorectal cancer epithelial-mesenchymal transition and progression via CCL5/β-catenin/Slug pathway.
Chen K; Liu Q; Tsang LL; Ye Q; Chan HC; Sun Y; Jiang X
Cell Death Dis; 2017 May; 8(5):e2819. PubMed ID: 28542126
[TBL] [Abstract][Full Text] [Related]
11. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells.
Singh SK; Mishra MK; Eltoum IA; Bae S; Lillard JW; Singh R
Sci Rep; 2018 Jan; 8(1):1323. PubMed ID: 29358632
[TBL] [Abstract][Full Text] [Related]
12. Dose dependent effects of platelet derived chondroitinsulfate A on the binding of CCL5 to endothelial cells.
Weingart C; Nelson PJ; Krämer BK; Mack M
BMC Immunol; 2008 Dec; 9():72. PubMed ID: 19068144
[TBL] [Abstract][Full Text] [Related]
13. CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network.
Escola JM; Kuenzi G; Gaertner H; Foti M; Hartley O
J Biol Chem; 2010 Dec; 285(53):41772-80. PubMed ID: 21041313
[TBL] [Abstract][Full Text] [Related]
14. Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer.
Sax MJ; Gasch C; Athota VR; Freeman R; Rasighaemi P; Westcott DE; Day CJ; Nikolic I; Elsworth B; Wei M; Rogers K; Swarbrick A; Mittal V; Pouliot N; Mellick AS
Oncotarget; 2016 Dec; 7(51):85437-85449. PubMed ID: 27863423
[TBL] [Abstract][Full Text] [Related]
15. The potential to target CCL5/CCR5 in breast cancer.
Velasco-Velázquez M; Xolalpa W; Pestell RG
Expert Opin Ther Targets; 2014 Nov; 18(11):1265-75. PubMed ID: 25256399
[TBL] [Abstract][Full Text] [Related]
16. Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy.
Nie Y; Huang H; Guo M; Chen J; Wu W; Li W; Xu X; Lin X; Fu W; Yao Y; Zheng F; Luo ML; Saw PE; Yao H; Song E; Hu H
Clin Cancer Res; 2019 Jul; 25(13):3873-3886. PubMed ID: 30890553
[TBL] [Abstract][Full Text] [Related]
17. The CCL5/CCR5 Axis Promotes Vascular Smooth Muscle Cell Proliferation and Atherogenic Phenotype Switching.
Lin CS; Hsieh PS; Hwang LL; Lee YH; Tsai SH; Tu YC; Hung YW; Liu CC; Chuang YP; Liao MT; Chien S; Tsai MC
Cell Physiol Biochem; 2018; 47(2):707-720. PubMed ID: 29794461
[TBL] [Abstract][Full Text] [Related]
18. Functional role of CCL5/RANTES for HCC progression during chronic liver disease.
Mohs A; Kuttkat N; Reißing J; Zimmermann HW; Sonntag R; Proudfoot A; Youssef SA; de Bruin A; Cubero FJ; Trautwein C
J Hepatol; 2017 Apr; 66(4):743-753. PubMed ID: 28011329
[TBL] [Abstract][Full Text] [Related]
19. Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia.
Lin S; Wan S; Sun L; Hu J; Fang D; Zhao R; Yuan S; Zhang L
Cancer Sci; 2012 May; 103(5):904-12. PubMed ID: 22380870
[TBL] [Abstract][Full Text] [Related]
20. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions.
Aldinucci D; Lorenzon D; Cattaruzza L; Pinto A; Gloghini A; Carbone A; Colombatti A
Int J Cancer; 2008 Feb; 122(4):769-76. PubMed ID: 17935139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
